Literature DB >> 23858400

Viral vectors for vaccine applications.

Youngjoo Choi1, Jun Chang.   

Abstract

Traditional approach of inactivated or live-attenuated vaccine immunization has resulted in impressive success in the reduction and control of infectious disease outbreaks. However, many pathogens remain less amenable to deal with the traditional vaccine strategies, and more appropriate vaccine strategy is in need. Recent discoveries that led to increased understanding of viral molecular biology and genetics has rendered the used of viruses as vaccine platforms and as potential anti-cancer agents. Due to their ability to effectively induce both humoral and cell-mediated immune responses, viral vectors are deemed as an attractive alternative to the traditional platforms to deliver vaccine antigens as well as to specifically target and kill tumor cells. With potential targets ranging from cancers to a vast number of infectious diseases, the benefits resulting from successful application of viral vectors to prevent and treat human diseases can be immense.

Entities:  

Keywords:  Adenoviridae; Alphavirus; Genetic vector; Poxviridae; Vaccines

Year:  2013        PMID: 23858400      PMCID: PMC3710930          DOI: 10.7774/cevr.2013.2.2.97

Source DB:  PubMed          Journal:  Clin Exp Vaccine Res        ISSN: 2287-3651


  61 in total

1.  Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.

Authors:  Soumi Gupta; Fengmin Zhou; Catherine E Greer; Harold Legg; Tony Tang; Paul Luciw; Jan zur Megede; Susan W Barnett; John J Donnelly; Derek T O'Hagan; John M Polo; Michael Vajdy
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

2.  Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria.

Authors:  E G Rodrigues; F Zavala; D Eichinger; J M Wilson; M Tsuji
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

3.  A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.

Authors:  Catherine E Greer; Fengmin Zhou; Harold S Legg; Zequn Tang; Silvia Perri; Barbara A Sloan; Jan Zur Megede; Yasushi Uematsu; Michael Vajdy; John M Polo
Journal:  Vaccine       Date:  2006-08-07       Impact factor: 3.641

4.  Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

Authors:  R M Conry; M B Khazaeli; M N Saleh; K O Allen; D L Barlow; S E Moore; D Craig; R B Arani; J Schlom; A F LoBuglio
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

5.  Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.

Authors:  P Colmenero; P Liljeström; M Jondal
Journal:  Gene Ther       Date:  1999-10       Impact factor: 5.250

6.  Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model.

Authors:  Bing Ni; Wenda Gao; Bo Zhu; Zhihua Lin; Zhengcai Jia; Wei Zhou; Jianping Zhao; Li Wang; Yuzhang Wu
Journal:  Cancer Immunol Immunother       Date:  2005-01-27       Impact factor: 6.968

7.  Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif.

Authors:  Oscar Bruna-Romero; Carolina D Rocha; Moriya Tsuji; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

8.  Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity.

Authors:  Marka Crittenden; Michael Gough; Kevin Harrington; Ken Olivier; Jill Thompson; Richard G Vile
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 9.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

Authors:  Anne Moon Crompton; David H Kirn
Journal:  Curr Cancer Drug Targets       Date:  2007-03       Impact factor: 3.428

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  43 in total

1.  Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.

Authors:  Cyrielle Fougeroux; Louise Turner; Anders Miki Bojesen; Thomas Lavstsen; Peter Johannes Holst
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

2.  Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36.

Authors:  H-N Na; J-H Nam
Journal:  Int J Obes (Lond)       Date:  2014-03-11       Impact factor: 5.095

Review 3.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

Review 4.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 5.  Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.

Authors:  Jeremy J Kudrna; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Vaxvec: The first web-based recombinant vaccine vector database and its data analysis.

Authors:  Shunzhou Deng; Carly Martin; Rasika Patil; Felix Zhu; Bin Zhao; Zuoshuang Xiang; Yongqun He
Journal:  Vaccine       Date:  2015-09-25       Impact factor: 3.641

7.  Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System.

Authors:  Hao Chen; Thomas M B Ware; Josephine Iaria; Hong-Jian Zhu
Journal:  J Vis Exp       Date:  2018-07-30       Impact factor: 1.355

Review 8.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

Review 9.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

Review 10.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.